Scoping Review of Interventions Associated with Cost Avoidance Able to Be Performed in the Intensive Care Unit and Emergency Department
- 21 January 2019
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 39 (3) , 215-231
Abstract
A framework for evaluating pharmacists’ impact on cost avoidance in the intensive care unit (ICU) and emergency department (ED) has not been established. This scoping review was registered (CRD42018091217) and conducted to identify, aggregate, and qualitatively describe the highest quality evidence for cost avoidance generated by clinical pharmacists on interventions performed in an ICU or ED. Searches were conducted in PubMed, Scopus, CINAHL, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews from inception until April 2018. The level of evidence (LOE) for each specific category of intervention was evaluated according to the Grading of Recommendations, Assessment, Development and Evaluation evidence‐to‐decision framework. The risks of bias for articles were evaluated using Newcastle Ottawa and Cochrane Collaboration tools. The values from all interventions were inflated to 2018 U.S. dollars using the consumer price index for medical care. Of the 464 articles initially identified, 371 were excluded and 93 were included. After reviewing references from the articles included, an additional 71 articles were also reviewed. The 38 cost intervention categories were supported by varying LOEs: IA (0 categories), IB (1 category), IIA (4 categories), IIB (0 categories), III (27 categories), and IV (6 categories), and articles mostly displayed low to moderate risks of bias. Pharmacists generate cost avoidance through a variety of interventions in critically and emergently ill patients. The quality of evidence supporting specific cost avoidance values is generally low. Quantification of and factors associated with the cost avoidance generated from pharmacists caring for these patients are of paramount importance.Keywords
This publication has 63 references indexed in Scilit:
- Economic Impact of Ventilator-Associated Pneumonia in a Large Matched CohortInfection Control & Hospital Epidemiology, 2012
- Prescribing authority for pharmacistsAmerican Journal of Health-System Pharmacy, 2011
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Cost Savings Associated with a Dedicated Drug Information Service in an Academic Medical CenterHospital Pharmacy, 2011
- Rapid-Response TeamsNew England Journal of Medicine, 2011
- Critical care medicine in the United States 2000–2005: An analysis of bed numbers, occupancy rates, payer mix, and costs*Critical Care Medicine, 2010
- Documentation of pharmacists’ interventions in an emergency department and associated cost avoidanceAmerican Journal of Health-System Pharmacy, 2007
- Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settingsJournal of Thrombosis and Haemostasis, 2006
- Position paper on critical care pharmacy servicesCritical Care Medicine, 2000
- Impact of a clinical pharmacist in a multidisciplinary intensive care unitCritical Care Medicine, 1994